实验研究
ENGLISH ABSTRACT
加替沙星眼用凝胶不同点眼频次兔眼组织药代动力学比较
王小桐
赵欣
祖薇
沈旭
陈世超
杨强
作者及单位信息
·
DOI: 10.3760/cma.j.cn115989-20220513-00215
Comparison of the pharmacokinetics of gatifloxacin ophthalmic gel in rabbit ocular tissues with different dosing frequencies
Wang Xiaotong
Zhao Xin
Zu Wei
Shen Xu
Chen Shichao
Yang Qiang
Authors Info & Affiliations
Wang Xiaotong
Shenyang Xingqi Pharmaceutical Co., Ltd., Shenyang 110164, China
Zhao Xin
Shenyang Xingqi Pharmaceutical Co., Ltd., Shenyang 110164, China
Zu Wei
Shenyang Xingqi Pharmaceutical Co., Ltd., Shenyang 110164, China
Shen Xu
Shenyang Xingqi Pharmaceutical Co., Ltd., Shenyang 110164, China
Chen Shichao
Shenyang Xingqi Pharmaceutical Co., Ltd., Shenyang 110164, China
Yang Qiang
Shenyang Xingqi Pharmaceutical Co., Ltd., Shenyang 110164, China
·
DOI: 10.3760/cma.j.cn115989-20220513-00215
363
36
0
0
1
0
PDF下载
APP内阅读
摘要

目的建立一种测定兔眼组织中加替沙星浓度的方法,并比较加替沙星眼用凝胶兔眼单次和多次点眼后在眼组织及血浆中的药代动力学特征。

方法取94只健康新西兰兔。任意选取10只新西兰兔不给予任何药物用于空白组织获取,将剩余84只按照随机数字表法随机分成单次给药组36只和多次给药组48只,雌雄各半,均取左眼为实验眼。单次给药组左眼给予1滴加替沙星眼用凝胶,分别于点眼后0.5、1、3、5、7、10 h收集泪液后进行心脏取血并处死,分别取房水、结膜、角膜、巩膜、虹膜-睫状体、晶状体、玻璃体、视网膜和脉络膜;多次给药组左眼每次给予1滴加替沙星眼用凝胶,每天3次,分别于连续给药第4和第6天首次给药后0.5 h,第7天首次给药后0.5、1、3、5、7、10 h进行心脏取血和眼组织收集。采用甲醇沉淀蛋白法预处理各样本,采用高效液相色谱串联质谱法测定并计算实验兔血浆及眼组织中加替沙星的达峰浓度(C max)、达峰时间(T max)、曲线下面积(AUC)等药代动力学参数,流动相采用甲醇-0.1%乙酸水溶液(体积比=70∶30),采用正离子多反应检测模式,以环丙沙星为内标物,并参照《中国药典》(2020年版)9012生物样品定量分析方法验证指导原则对方法的选择性、标准曲线和定量下限、准确度和精密度、提取回收率和基质效应、稳定性进行验证。结合加替沙星对眼部常见感染菌的最小抑菌浓度(MIC 90),计算各组织和血浆C max/MIC 90和AUC/MIC 90值。

结果加替沙星在各眼组织和血浆中线性关系良好;角膜组织中的日间准确度为-1.5%~6.0%,日间精密度≤15%;角膜组织中的提取回收率为92.0%~94.8%,经内标归一化计算得到的低、中、高浓度的基质效应精密度均不大于3.3%,单次给药后加替沙星在眼前节和后节组织均有较高的药物浓度分布,AUC 0-t从高到低分别为泪液、角膜、结膜、虹膜-睫状体、巩膜、房水、脉络膜、视网膜、晶状体和玻璃体,C max分别为94.90 μg/g、7.34 μg/g、3.65 μg/g、1.81 μg/g、1.75 μg/g、1.31 μg/ml、0.86 μg/g、0.53 μg/g、0.13 μg/g、0.07 μg/ml,除晶状体、脉络膜和玻璃体液中的T max为0.5 h,其余各组织T max均为1 h。多次给药第4、6、7天的0.5 h各眼部组组织中加替沙星浓度比较,差异无统计学意义( P>0.05),且角膜、结膜和巩膜中AUC 0-t约为单次给药的2.04、2.12和2.32倍。单、多次给药后进入体循环的加替沙星浓度均低于25.00 ng/ml。对于金黄色葡萄球菌和表皮葡萄球菌,加替沙星眼用凝胶连续用药后在眼前节结膜、角膜、巩膜、虹膜-睫状体、房水和脉络膜中的药代动力学/药效学均可满足C max/MIC 90≥10且AUC/MIC 90≥30。

结论成功构建快速灵敏的眼组织加替沙星浓度测量方法。加替沙星眼用凝胶以每天3次点眼连续用药3 d后眼组织可达到稳态浓度,且比单次给药在眼组织浓度升高。局部使用加替沙星眼用凝胶可实现眼部结膜、角膜、巩膜、虹膜-睫状体常见感染细菌的有效治疗。

加替沙星;眼用凝胶;高效液相色谱串联质谱法;兔;药代动力学
ABSTRACT

ObjectiveTo establish a method for determining the concentration of gatifloxacin in rabbit ocular tissue and compare the ocular pharmacokinetics of 0.3% gatifloxacin eye gel after a single and multiple topical instillations in rabbits.

MethodsNinety-four healthy New Zealand rabbits were selected.Ten rabbits were randomly selected without any treatment for blank tissue collection, and the remaining 84 rabbits were randomly divided into a single-dose group (36 rabbits) and a multiple-dose group (48 rabbits) equally between males and females using a random number table.The left eye was taken as the experimental eye.The single-dose group was given one drop of 0.3% gatifloxacin eye gel into the left eyes, and the rabbits were divided evenly into six subgroups.In each subgroup, tear specimens and blood specimens were collected at 0.5, 1, 3, 5, 7, 10 hours after gel application, then cardiac blood samples were taken, after which animals were sacrificed immediately to collect ocular tissue including aqueous humor, conjunctiva, cornea, sclera, iris-ciliary body, lens, vitreous body, retina, and choroid.The multiple-dose group was given 1 drop of gatifloxacin ophthalmic gel in the left eye three times a day.At 0.5 hour after the first administration days 4 and 6, and 0.5, 1, 3, 5, 7, and 10 hours after the first administration on day 7, the cardiac blood sampling and ocular tissue collection were performed.The methanol precipitation protein method was used to pretreat samples, and the concentration of gatifloxacin in rabbit plasma and eye tissue was measured and calculated by high-performance liquid chromatography-tandem mass spectrometry method to obtain pharmacokinetic-related parameters such as peak concentration (C max), peak time (T max), and area under curve (AUC).The mobile phase was a methanol-0.1% acetic acid aqueous solution (volume ratio=70∶30), and a positive ion multiple reaction detection mode was used.Ciprofloxacin was used as the internal standard, the selectivity, standard curve and lower limit of quantification, accuracy and precision, extraction recovery rate, matrix effect, and stability of the method were validated in accordance with the 9012 Guidelines for Validation of Quantitative Analysis Methods for Biological Samples in Chinese Pharmacopoeia ( 2020 edition).Combined with the minimum inhibitory concentration (MIC 90) of gatifloxacin on common ocular infectious bacteria, C max/MIC 90 and AUC/MIC 90 were calculated.The study protocol was reviewed and approved by the Animal Ethics Committee of Shenyang Xingqi Pharmaceutical Co., Ltd.(No.XQ-2016-011).

ResultsGatifloxacin has a good linear relationship in various eye tissues and plasma.The between-run precision in corneal tissue is within the range of -1.5%-6.0%, and the daytime precision was not greater than 15%.The extraction recovery rate in corneal tissue ranged from 92.0% to 94.8%, and the precision of the matrix effect at low, medium, and high concentrations calculated by internal standard normalization was not greater than 3.3%.After a single topical instillation, gatifloxacin reached a high concentration in anterior and posterior segment ocular tissues and its distribution ranked in order from the highest to the lowest by AUC 0-t as follows, tears, cornea, conjunctiva, iris-ciliary body, sclera, aqueous humor, choroid, retina, lens and vitreous body, with the C max of 94.90 μg/g, 7.34 μg/g, 3.65 μg/g, 1.81 μg/g, 1.75 μg/g, 1.31 μg/ml, 0.86 μg/g, 0.53 μg/g, 0.13 μg/g and 0.07 μg/ml, respectively.T max was 1 hour in all ocular tissues except in the lens, choroid, and vitreous body fluid, where T max was 0.5 hour.There was no significant difference among the concentrations of gatifloxacin in ocular tissues at 0.5 hour on days 4, 6 and 7 after multiple dosing ( P>0.05), and the AUC 0-t in the cornea, conjunctiva, and sclera was approximately 2.04, 2.12, and 2.32 times that of the single dosing.The concentration of gatifloxacin released into the systemic circulation after single and multiple dosing was less than 25.00 ng/ml.For both Staphylococcus aureus and Staphylococcus epidermidis, pharmacokinetic/pharmacodynamics in the conjunctiva, cornea, sclera, iris-ciliary body, aqueous humor, and choroid were satisfied with C max/MIC 90≥10 and AUC/MIC 90≥30 after continuous administration of gatifloxacin ophthalmic gel.

ConclusionsA rapid and sensitive method for measuring gatifloxacin concentration in ocular tissues is successfully constructed.Gatifloxacin ophthalmic gel administered three times a day for three days can achieve stable concentrations in ocular tissues, and the concentration of gatifloxacin in ocular tissues is increased compared with a single dose.Effective treatment of common bacterial infections of the conjunctiva, cornea, sclera, and iris-ciliary body can be achieved with topical application of gatifloxacin ophthalmic gel.

Gatifloxacin;Ocular administration, gels;Liquid chromatography-tandem mass spectrometry, high-performance;Rabbits;Pharmacokinetics
Yang Qiang, Email: mocdef.iabqnisgnaiqgnay
引用本文

王小桐,赵欣,祖薇,等. 加替沙星眼用凝胶不同点眼频次兔眼组织药代动力学比较[J]. 中华实验眼科杂志,2024,42(07):621-628.

DOI:10.3760/cma.j.cn115989-20220513-00215

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
眼部感染如不及时治疗可导致不可逆转的视力丧失。局部使用抗生素,如喹诺酮类药物,是治疗眼部细菌感染的主要方式 [ 1 , 2 ]。加替沙星是一种第4代喹诺酮类抗菌药物,具有同时抑制细菌DNA回旋酶和拓扑异构酶Ⅳ的双靶点作用,其在保留第3代对革兰阴性菌抗菌活性的基础上,增强了对革兰阳性菌、厌氧菌、支原体、衣原体的抗菌活性 [ 3 ]。临床研究也表明,加替沙星的抗革兰阳性菌眼部感染效果显著优于左氧氟沙星,同时还能显著降低白内障围手术期眼内炎的发生率 [ 4 , 5 , 6 ]。Gao等 [ 7 ]对从中国眼部细菌感染患者分离的3 690株细菌进行研究发现,这些病原菌对加替沙星的敏感性最高,达到90.01%,而对左氧氟沙星的敏感性仅为51.91%,因此加替沙星比左氧氟沙星更适合眼部感染的预防和治疗。局部点眼是治疗眼前节疾病的首选 [ 8 ]。滴眼液在临床上的应用较为广泛,但其药物吸收入眼的速度缓慢、程度不足,导致生物利用度仅为1%~7% [ 9 , 10 ]。凝胶是一种药物智能化运载系统,具有制备简单、使用方便、滞留时间长等优点,是特别适合眼部给药的载体 [ 11 , 12 ]。Ding等 [ 13 ]研究发现,白内障超声乳化术前应用加替沙星眼用凝胶患者的房水中加替沙星浓度比术前应用加替沙星滴眼液的患者高,且作用时间长。还有研究表明,加替沙星眼用凝胶比加替沙星滴眼液兔眼单次给药在角膜、结膜和房水中具有更高的药物浓度 [ 14 ]。目前,相关研究多采用液相色谱法对加替沙星进行检测,样品出峰时间长,且定量限较高,不适用于眼后段组织和体液循环浓度监测,且未对不同给药频次的眼组织药代动力学进行分析。本研究建立一种基于高效液相色谱串联质谱法(high-performance liquid chromatography-tandem mass spectrometry,HPLC-MS/MS)的灵敏、专属的眼组织及血浆加替沙星浓度测定方法,并采用该方法对加替沙星眼用凝胶不同点眼频次兔眼组织药代动力学进行研究,为更合理的临床用药提供参考。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Pawar P Katara R Mishra S et al. Topical ocular delivery of fluoroquinolones[J]. Expert Opin Drug Deliv 201310(5)∶691711. DOI: 10.1517/17425247.2013.772977 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Christopher KL Hood CT Mian SI et al. Endophthalmitis in advanced microbial keratitis:risk factors and examination findings[J]. Cornea 202039(9)∶10961101. DOI: 10.1097/ICO.0000000000002349 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Hezhen T Shuying W Xiaoli Z et al. Effect of gatifloxacin in the treatment of ophthalmological diseases and continuous nursing intervention[J]. Pak J Pharm Sci 201831(4(Special))∶17071712.
返回引文位置Google Scholar
百度学术
万方数据
[4]
Scoper SV . Review of third-and fourth-generation fluoroquinolones in ophthalmology: in - vitro and in - vivo efficacy [J]. Adv Ther 200825(10)∶979994. DOI: 10.1007/s12325-008-0107-x .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Mather R Karenchak LM Romanowski EG et al. Fourth generation fluoroquinolones:new weapons in the arsenal of ophthalmic antibiotics[J]. Am J Ophthalmol 2002133(4)∶463466. DOI: 10.1016/s0002-9394(02)01334-x .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Jensen MK Fiscella RG Moshirfar M et al. Third- and fourth-generation fluoroquinolones:retrospective comparison of endophthalmitis after cataract surgery performed over 10 years[J]. 200834(9)∶14601467.
返回引文位置Google Scholar
百度学术
万方数据
[7]
Gao W Xia T Chen HB et al. Ocular bacterial infections at a tertiary eye center in China:a 5-year review of pathogen distribution and antibiotic sensitivity[J]. Int J Ophthalmol 202013(1)∶5460. DOI: 10.18240/ijo.2020.01.08 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Gaudana R Ananthula HK Parenky A et al. Ocular drug delivery[J]. AAPS J 201012(3)∶348360. DOI: 10.1208/s12248-010-9183-3 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Durairaj C Ocular pharmacokinetics[J]. Handb Exp Pharmacol 20172423155. DOI: 10.1007/164_2016_32 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Urtti A Challenges and obstacles of ocular pharmacokinetics and drug delivery[J]. Adv Drug Deliv Rev 200658(11)∶11311135. DOI: 10.1016/j.addr.2006.07.027 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Pandey M Choudhury H Binti Abd Aziz A et al. Potential of stimuli-responsive in situ gel system for sustained ocular drug delivery:recent progress and contemporary research[J/OL]. Polymers (Basel) 202113(8)∶1340[2023-09-10]. http://www.ncbi.nlm.nih.gov/pubmed/33923900. DOI: 10.3390/polym13081340 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Alkholief M Kalam MA Almomen A et al. Thermoresponsive sol-gel improves ocular bioavailability of Dipivefrin hydrochloride and potentially reduces the elevated intraocular pressure in vivo [J]. Saudi Pharm J 202028(8)∶10191029. DOI: 10.1016/j.jsps.2020.07.001 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Ding W Ni W Chen H et al. Comparison of drug concentrations in human aqueous humor after the administration of 0.3% gatifloxacin ophthalmic gel,0.3% gatifloxacin and 0.5% levofloxacin ophthalmic solutions[J]. Int J Med Sci 201512(6)∶517523. DOI: 10.7150/ijms.11376 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
孙飒周天洋夏慧云加替沙星眼用凝胶制剂与加替沙星滴眼液兔眼药动学的比较[J]. 医学研究杂志 201746(2)∶116119. DOI: 10.11969/j.issn.1673-548X.2017.02.030 .
返回引文位置Google Scholar
百度学术
万方数据
Sun S Zhou TY Xia HY et al. Comparion of the pharmacokinetics of gatifloxacin ophthalmic gel with gatifloxacin rye drops in rabbbits[J]. J Med Res 201746(2)∶116119. DOI: 10.11969/j.issn.1673-548X.2017.02.030 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[15]
Callegan MC Ramirez R Kane ST et al. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens[J]. Adv Ther 200320(5)∶246252. DOI: 10.1007/BF02849853 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Wright DH Brown GH Peterson ML et al. Application of fluoroquinolone pharmacodynamics[J]. J Antimicrob Chemother 200046(5)∶669683. DOI: 10.1093/jac/46.5.669 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Craig WA . Does the dose matter?[J]. Clin Infect Dis 200133Suppl 3S233237. DOI: 10.1086/321854 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Gao W Xia T Chen HB et al. Ocular bacterial infections at a tertiary eye center in China:a 5-year review of pathogen distribution and antibiotic sensitivity[J]. Int J Ophthalmol 202013(1)∶5460.
返回引文位置Google Scholar
百度学术
万方数据
[19]
Liu C Ding B Ji J et al. Microbial spectrum and resistance patterns in ocular infections:a 15-year review in East China[J]. Infect Drug Resist 20211421652171. DOI: 10.2147/IDR.S314647 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
孙声桃王丽娅张月琴近六年眼部分离细菌及体外药物敏感性的变迁[J]. 中华眼科杂志 201248(6)∶542547. DOI: 10.3760/cma.j.issn.0412-4081.2012.06.013 .
返回引文位置Google Scholar
百度学术
万方数据
Sun ST Wang LY Zhang YQ et al. The changes of ocular bacterial isolates and in vitro antimicrobial susceptibility in the past six years [J]. Chin J Ophthalmol 201248(6)∶542547. DOI: 10.3760/cma.j.issn.0412-4081.2012.06.013 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[21]
Mizuno K Koide T Shimada S et al. Route of penetration of topically instilled nipradilol into the ipsilateral posterior retina[J]. Invest Ophthalmol Vis Sci 200950(6)∶28392847. DOI: 10.1167/iovs.08-2922 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Gote V Sikder S Sicotte J et al. Ocular drug delivery:present innovations and future challenges[J]. J Pharmacol Exp Ther 2019370(3)∶602624. DOI: 10.1124/jpet.119.256933 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Khan S Warade S Singhavi DJ . Improvement in ocular bioavailability and prolonged delivery of tobramycin sulfate following topical ophthalmic administration of drug-loaded mucoadhesive microparticles incorporated in thermosensitive in situ gel[J]. J Ocul Pharmacol Ther 201834(3)∶287297. DOI: 10.1089/jop.2017.0079 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Liu JD Yang YC Tang H Gatifloxacin-containing ophthalmic gel and preparation method thereof:US8901131B2[P/OL]. 2014-12-02[2023-10-18]. http://patents.google.com/patent/US8901131B2/en.
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
杨强,Email: mocdef.iabqnisgnaiqgnay
B

王小桐:参与选题、数据采集、分析/解释数据、起草及修改文章;赵欣:设计实验、分析/解释数据;祖薇:参与动物实验、样品前处理;沈旭:参与动物实验、数据采集/分析;陈世超:参与动物实验、数据采集及分析;杨强:酝酿/设计实验、对文章知识性内容做批评性审阅及文章定稿

C
王小桐、赵欣、祖薇、沈旭、陈世超、杨强均为沈阳兴齐眼药股份有限公司职工;本文中提及获得中国国家知识产权局发明专利(专利号:CN102078284B)和美国专利(专利号:US8901131B2)的加替沙星眼用凝胶技术均由沈阳兴齐眼药股份有限公司申请
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号